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A B S T R A C T
The highly progressive neuromuscular disorder dystrophinopathy is triggered by primary abnormalities in the
Dmd gene, which causes cytoskeletal instability and loss of sarcolemmal integrity. Comparative organellar
proteomics was employed to identify sarcolemma-associated proteins with an altered concentration in dys-
trophic muscle tissue from the mdx-4cv mouse model of dystrophinopathy. A lectin agglutination method was
used to prepare a sarcolemma-enriched fraction and resulted in the identification of 190 significantly changed
protein species. Proteomics established differential expression patterns for key components of the muscle plasma
membrane, cytoskeletal network, extracellular matrix, metabolic pathways, cellular stress response, protein
synthesis, immune response and neuromuscular junction. The deficiency in dystrophin and drastic reduction in
dystrophin-associated proteins appears to trigger (i) enhanced membrane repair involving myoferlin, dysferlin
and annexins, (ii) increased protein synthesis and the compensatory up-regulation of cytoskeletal proteins, (iii)
the decrease in the scaffolding protein periaxin and myelin PO involved in myelination of motor neurons, (iv)
complex changes in bioenergetic pathways, (v) elevated levels of molecular chaperones to prevent proteotoxic
effects, (vi) increased collagen deposition causing reactive myofibrosis, (vii) disturbed ion homeostasis at the
sarcolemma and associated membrane systems, and (viii) a robust inflammatory response by the innate immune
system in response to chronic muscle damage.
Significance: Duchenne muscular dystrophy is a devastating muscle wasting disease and represents the most
frequently inherited neuromuscular disorder in humans. Genetic abnormalities in the Dmd gene cause a loss of
sarcolemmal integrity and highly progressive muscle fibre degeneration. Changes in the neuromuscular system
are associated with necrosis, fibrosis and inflammation. In order to evaluate secondary changes in the sarco-
lemma membrane system due to the lack of the membrane cytoskeletal protein dystrophin, comparative orga-
nellar proteomics was used to study the mdx-4cv mouse model of dystrophinopathy. Mass spectrometric analyses
identified a variety of altered components of the extracellular matrix-sarcolemma-cytoskeleton axis in dystrophic
muscles. This included proteins involved in membrane repair, cytoskeletal restoration, calcium homeostasis,
cellular signalling, stress response, neuromuscular transmission and reactive myofibrosis, as well as immune cell
infiltration. These pathobiochemical alterations agree with the idea of highly complex secondary changes in X-
linked muscular dystrophy and support the concept that micro-rupturing of the dystrophin-deficient plasma
membrane is at the core of muscle wasting pathology.
1. Introduction
Skeletal muscle fibres endure high levels of load bearing and cel-
lular shape change during lateral force transmission. The sarcolemma
and its tight association with the basal lamina and associated extra-
cellular matrix on the one hand, and bridging costameres and
underlying intracellular cytoskeletal networks on the other hand, play a
central role in the cytoarchitectural provision of mechanical stability
for extended periods of excitation-contraction-relaxation cycles [1–3].
Mutations in genes that encode sarcolemma-associated or costamere-
linked proteins, such as desmin, plectin, vinculin, talin, integrin or
dystrophin and its associated glycoprotein complex, cause many types
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of muscular dystrophy [4]. Besides being of crucial importance for the
protection of fibre integrity, the specialized and semi-permeable muscle
plasmalemma and its invaginations also function as a physiological
barrier with highly select cellular signalling, uptake and release me-
chanisms. This includes the provision of the subcellular structures,
physiological systems and supramolecular complexes for efficient neu-
rotransmission at the junctional folds, the propagation of action po-
tentials towards the transverse tubular system, and excitation-contrac-
tion coupling from the neuromuscular junction towards the muscle
interior [5].
The sarcolemma supports overall fibre shape and tissue elasticity in
conjunction with the flexible components of the contractile apparatus
and the attachment to the cytoskeleton. A key component involved in
this process is the membrane cytoskeletal protein dystrophin [6], of
which the full-length isoform Dp427-M [7] forms a scaffold for an-
choring a variety of sarcolemmal proteins [8]. The dystrophin-glyco-
protein complex provides the stabilising linkage between laminin-211
of the basal lamina and the cortical actin membrane cytoskeleton [9],
besides being involved in signalling events at the muscle surface [10].
In the highly progressive muscle wasting disorder Duchenne muscular
dystrophy, primary abnormalities in the Dmd gene cause the almost
complete loss of full-length dystrophin and a concomitant reduction in
dystrophin-associated proteins [11].
Mass spectrometry-based proteomics represents an ideal bioanaly-
tical tool to investigate the complex secondary changes in dystrophin-
deficient muscle tissues [12]. A variety of proteomic studies have
analysed tissue extracts from various muscle types of animal models of
X-linked muscular dystrophy [13–20]. Proteome-wide alterations were
shown to occur in the contractile apparatus, metabolic pathways, sig-
nalling mechanisms, ion homeostasis, the cytoskeleton, the extra-
cellular matrix and the cellular stress response [21–23]. In analogy, the
study described here has extended and refined the proteomic survey of
dystrophic skeletal muscles by focusing on the mass spectrometric
identification of altered proteins in the sarcolemma-enriched fraction
from the mdx-4cv animal model of dystrophinopathy. This particular
genetic mouse model is lacking dystrophin due to a mutation in exon 53
[24] and the frequency of revertant fibres is considerably less as com-
pared to the mdx mouse [25], which exhibits a mutation in exon 23
[26]. In this new and focused proteomic study, an agglutination affinity
method was employed to isolate an enriched sarcolemmal preparation
[27]. Sarcolemmal proteins present only a small percentage of the
overall muscle protein constellation [28], which consists mostly of
contractile and metabolic proteins [29]. This makes the proteomic
evaluation of the sarcolemma membrane system technically challen-
ging. However, since the primary pathobiochemical insult in dystro-
phinopathy is located in the sub-sarcolemmal cytoskeleton, it was of
interest to study the closely associated sarcolemmal environment of the
dystrophin network by organellar proteomics [30].
It is important to state that the interpretation of findings from
subproteomic studies may be complicated due to both technical and
pathobiochemical issues. On the one hand, subcellular fractionation
procedures clearly reduce sample complexity and thus enable the
analysis of low-abundance components, but on the other hand, the
application of extensive isolation procedures for the enrichment of
distinct membrane fractions may introduce potential bioanalytical ar-
tefacts. Complex pathophysiological processes, such as inflammation,
necrosis or fibrosis [22], as well as cellular adaptations, may therefore
distort the efficient isolation of distinct organelles and subsequent
comparative proteomic profiling of mutant versus wild type membrane
systems. However, independent verification experiments using im-
munoblotting or immunofluorescence microscopy can usually be used
to confirm key findings from mass spectrometric surveys, and thus
enable the objective evaluation of the validity of pathoproteomic pro-
files [12].
A select number of investigations that have utilized a combination
of mass spectrometry, subcellular fractionation and interaction
proteomics to study the dystrophin complex have confirmed the orga-
nization of the core complex consisting of dystrophin isoform Dp427-M,
dystroglycans, sarcoglycans, sarcospan, syntrophins and dystrobrevins
[27,31–33]. Additional linkages within the dystrophin complexome
were shown to occur with nitric oxide synthase, biglycan, cytokeratin,
synemin and the cytoskeletal linker desmoglein [34–38]. The findings
from the proteomic survey described in this report have identified a
variety of proteins of the basement membrane-sarcolemma-cytoske-
leton axis with a significantly changed abundance in dystrophic mus-
cles. This included sarcolemmal proteins, extracellular matrix compo-
nents, cytoskeletal proteins and components of the motor neuron and
associated glia cells. In addition, marker proteins of invading immune
cells were detected at elevated levels indicating a considerable response
by the innate immune system, which agrees with the occurrence of
sterile inflammation in damaged muscle tissues.
2. Methods
2.1. Materials
For the comparative proteomic analysis of enriched sarcolemma
preparations from wild type versus dystrophic mdx-4cv skeletal muscle,
a variety of general analytical grade reagents and materials were ob-
tained from GE Healthcare (Little Chalfont, Buckinghamshire, UK), Bio-
Rad Laboratories (Hemel-Hempstead, Hertfordshire, UK) and Sigma
Chemical Company (Dorset, UK). Ultrapure acrylamide stock solutions
were purchased from National Diagnostics (Atlanta, GA, USA), se-
quencing grade modified trypsin and Lys-C were obtained from
Promega (Madison, WI, USA) and Whatman nitrocellulose transfer
membranes came from Invitrogen (Carlsbad, CA, USA). The chemilu-
minescence substrate and protease inhibitors were purchased from
Roche Diagnostics (Mannheim, Germany). Primary antibodies for im-
munoblotting and immunofluorescence microscopy were purchased
from Abcam, Cambridge, UK (ab43125 to β-dystroglycan, ab124798 to
desmoglein isoform DSG1, ab2413 to fibronectin, ab58562 to biglycan,
and ab124684 to dysferlin), LifeSpan Biosciences, Seattle, WA, USA
(LS-B11314 to myoferlin), Sigma Chemical Company, Dorset, UK
(L9393 to laminin), EMD Millipore, Schwalbach am Taunus, Germany
(ABN363 to myelin PO protein), BD Transduction Laboratories,
Heidelberg, Germany (A14020 to annexin A2), and NovoCastra, Leica
Biosystems, Newcastle Upon Tyne, UK (NCL-Dys2 to the carboxy ter-
minus of dystrophin isoform Dp427). Chemicon International
(Temecula, CA, USA) provided peroxidase-conjugated secondary anti-
bodies. For immunofluorescence microscopy, normal goat serum and
goat-anti-mouse IgG RRX (Rhodamine Red-X) antibodies were pur-
chased from Molecular Probes, Life Technologies (Darmstadt,
Germany). The embedding medium Fluoromount G was from Southern
Biotech (Birmingham, AL, USA). Purified wheat germ lectin, N-acetyl-
D-glucosamine and bis-benzimide Hoechst-33342 were obtained from
Sigma Chemical Company (Dorset, UK).
2.2. Dystrophic mdx-4cv mouse model of Duchenne muscular dystrophy
First described in 1989 [39], the mdx-4cv mouse model was gen-
erated on the C57BL/6 background by chemical mutagenesis using N-
ethyl-nitrosourea. The induced C to T transition at base 7916 in exon 53
of the dystrophin gene generates a premature stop codon, thus abro-
gating dystrophin synthesis. The mdx-4cv mouse exhibits a number of
histopathological features of dystrophinopathy and has the added ad-
vantage of possessing 10-fold fewer dystrophin-positive revertant fibres
than the conventionally used mdx mouse model [25]. For the identifi-
cation of global changes in the sarcolemmal proteome, total tissue ex-
tracts of hind limb muscle from 5-month-old control C57BL/6 mice and
age-matched mdx-4cv mice were obtained from the Bioresource Unit of
the University of Bonn. Mice were kept under standard conditions and
all procedures adhered to German and Irish legislation on the use of
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animals in experimental research. The animals were sacrificed by cer-
vical dislocation and hind limbs were carefully dissected and quick-
frozen in liquid nitrogen [16]. Samples were transported to Maynooth
University in accordance with the Department of Agriculture (animal
by-product register number 2016/16 to the Department of Biology,
National University of Ireland, Maynooth) and stored at−80 °C prior to
analysis.
2.3. Preparation of crude muscle microsomes from normal and dystrophic
hind leg muscle
Hind limb muscle specimens were from age-matched normal versus
dystrophic animals (4 g wet weight; n=3). For each biological re-
plicate three hind legs from three different mice were pooled. In total
nine hind legs were used to generate three biological replicates each for
wild-type and mdx-4cv specimens. The samples were finely chopped
and homogenised in 7.5 volumes of homogenisation buffer (20mM
sodium pyrophosphate, 20mM sodium phosphate, 1 mM MgCl2,
0.303M sucrose, 0.5mM EDTA, pH 7.0, supplemented with a protease
inhibitor cocktail [20]), using a hand-held IKA T10 Basic Homogeniser
from IKA Labortechnik (Staufen, Germany). Crude muscle homogenates
were kept on ice for 1.5 h and subsequently centrifuged at 14,000g for
15min at 4 °C. The protein containing supernatant was removed and
centrifuged at 100,000g for 1 h at 4 °C [40] using an Optima L-100 XP
ultracentrifuge from Beckman Coulter (Fullerton, CA, USA). The re-
sulting pellet containing crude microsomes was re-suspended in an
appropriate volume of 50mM sodium phosphate, 0.16M NaCl, pH 7.4.
2.4. Preparation of enriched sarcolemma by wheat germ agglutination
An enriched sarcolemma preparation was prepared from crude mi-
crosomes using age-matched wild type versus dystrophic mdx-4cv mice
with the help of an established lectin agglutination method, as pre-
viously described in detail [27,28,41]. Briefly, crude microsomes were
diluted with 50mM sodium phosphate, 0.16M NaCl, pH 7.4 to give a
final protein concentration of 1mg/ml. This suspension was added to
an equal volume of 1mg/ml wheat germ lectin in above buffer, mixed
gently and kept on ice for 10min. This mixture was pelleted at 14,000g
for 90 s. The supernatant from this centrifugation step contained non-
agglutinated vesicles. The pellet was re-suspended in 20mM Tris-HCl,
pH 7.4, 0.303M sucrose, and centrifuged again at 14,000g for 90 s. This
step was repeated once more. The resulting pellets were re-suspended
in the above described Tris buffer and de-agglutinated by incubation
with the competitive sugar 0.2M N-acetyl-D-glucosamine for 20min at
room temperature [28]. The de-agglutinated suspension was cen-
trifuged at 14,000g for 90 s, and the resulting supernatant was pelleted
at 150,000g for 20min at 4 °C in an Optima L-100 XP ultracentrifuge
(Beckman Coulter, Fullerton, CA, USA). The pellet from this step was
re-suspended in above buffer and centrifuged again at 150,000g for
20min at 4 °C. This pellet corresponds to a subcellular fraction enriched
in sarcolemma vesicles [41]. Membranes were re-suspended in an ap-
propriate volume of label-free solubilisation buffer (6M urea, 2M
thiourea, 10 mM Tris, pH 8.0 in LC-MS grade water) for subsequent
label-free mass spectrometry.
2.5. Sample preparation for label-free liquid chromatography mass
spectrometry
Protein concentrations of enriched sarcolemma samples were de-
termined using the Bradford assay system [42] and sample volumes
were then equalised with label-free solubilisation buffer. Samples for
LC-MS/MS analysis were reduced with 10mM dithiothreitol for 30min
at room temperature, and alkylated with 25mM iodoacteamide in
50mM ammonium bicarbonate for 20min at room temperature in the
dark. A further 10mM dithiothreitol was added to each sample and
then incubated for 15min at room temperature in the dark, to quench
any unreacted iodoacteamide [18]. Proteolytic digestion was achieved
using a combination of the enzymes Lys-C and trypsin. Samples were
first digested with sequencing grade Lys-C at a ratio of 1:100 (protea-
se:protein) and incubated at 37 °C for 4 h. Samples were then diluted
with four times the initial sample volume with 50mM ammonium bi-
carbonate, followed by digestion with sequencing grade modified
trypsin at a ratio of 1:25 (protease:protein) overnight at 37 °C [43]. The
addition of 2% trifluoroacetic acid (TFA) in 20% acetonitrile (ACN) (3:1
(v/v) dilution) was used to stop proteolytic digestion. The peptides
were purified using Pierce C18 spin columns from Thermo Fisher Sci-
entific (Dublin, Ireland), dried through vacuum centrifugation and re-
suspended in an appropriate volume of loading buffer (2% ACN, 0.05%
TFA in LC-MS grade water). Peptide suspensions were vortexed and
sonicated to aid full re-suspension. Samples were centrifuged briefly at
14,000g and the supernatant transferred to mass spectrometry vials.
2.6. Label-free liquid chromatography mass spectrometry
The label-free liquid chromatography mass spectrometric (LC-MS/
MS) analysis of enriched sarcolemma from wild type versus mdx-4cv
tissue was carried out using an Ultimate 3000 NanoLC system (Dionex
Corporation, Sunnyvale, CA, USA) coupled to a Q-Exactive mass spec-
trometer (Thermo Fisher Scientific). Peptide mixtures (4 μl, corre-
sponding to 0.8 μg protein) were loaded by an autosampler onto a C18
trap column (C18 PepMap, 300 μm id×5mm, 5 μm particle size, 100 Å
pore size; Thermo Fisher Scientific). The trap column was switched on-
line with an analytical Biobasic C18 Picofrit column (C18 PepMap,
75 μm id×50 cm, 2 μm particle size, 100 Å pore size; Dionex) [44].
Peptides were eluted from the column using the following binary gra-
dient: solvent A [2% (v/v) ACN and 0.1% (v/v) formic acid in LC-MS
grade water] and 0–90% solvent B [80% (v/v) ACN and 0.1% (v/v)
formic acid in LC-MS grade water]. The peptides were eluted as follows:
5–45% solvent B for the first 120min, 45–90% solvent B for 2.5min,
90% solvent B for 7min and 3% solvent B for 43min. The column flow
rate was set to 0.3 μl/min [45]. Data were acquired with Xcalibur
software (Thermo Fisher Scientific). The Q-Exactive was operated in
positive, data-dependent mode and was externally calibrated. Survey
MS scans were performed in the 300–1700m/z range with a resolution
of 140,000 (m/z 200) and lock mass set to 445.12003. CID (collision-
induced dissociation) fragmentation was carried out with the fifteen
most intense ions per scan and at 17,500 resolution. A dynamic ex-
clusion window was applied within 30 s. An isolation window of 2m/z
and one microscan were used to collect suitable tandem mass spectra.
Pre-run and post-run HeLa protein samples were analysed by Proteome
Discoverer 1.4 to verify the reproducibility of the LC-MS/MS system.
2.7. Protein profiling by label-free LC-MS/MS
To determine the degree of enrichment of sarcolemmal proteins and
potential dystrophin-associated proteins, mass spectrometric files were
first searched qualitatively against the UniProtKB-SwissProt Mus mus-
culus database using Proteome Discoverer 1.4 (Thermo Fisher) and
Sequest HT (SEQUEST HT algorithm, licence Thermo Scientific, regis-
tered trademark University of Washington, USA). The following settings
were used: (i) peptide mass tolerance set to 10 ppm, (ii) MS/MS mass
tolerance set to 0.02 Da, (iii) a maximum of two missed cleavages, (iv)
carbamidomethylation set as a fixed modification (v) methionine oxi-
dation set as a variable modification and (vi) peptide confidence set to
high. Subsequently Progenesis QI for Proteomics software (version 3.1;
Non-Linear Dynamics, a Waters company, Newcastle upon Tyne, UK)
was used for the quantitative analysis of enriched sarcolemma from
wild-type versus mdx-4cv skeletal muscle. A reference run was selected
and all other runs were aligned to this run, thus allowing for any drift in
retention time [46]. Prior to being exported as a MASCOT generic file
(mgf) to Proteome Discoverer 2.1 (Thermo Scientific) the MS/MS data
files were filtered using the following settings: (i) peptide features with
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ANOVA≤ 0.01 between experimental groups, (ii) mass peaks with
charge states from +1 to +5 and (iii) greater than one isotope per
peptide. Protein identification was performed using Proteome Dis-
coverer 2.1 against Mascot (version 2.3, Matrix Science, Boston, MA,
USA) and Sequest HT using the UniProtKB-SwissProt Mus musculus
database. The following search parameters were used: (i) peptide mass
tolerance set to 10 ppm, (ii) MS/MS mass tolerance set to 0.02 Da, (iii)
up to two missed cleavages, (iv) carbamidomethylation set as a fixed
modification and (v) methionine oxidation set as a variable modifica-
tion [47]. For re-importation back into Progenesis LC-MS software as a
PepXML file only peptides with either ion scores of 40.00 or more (from
Mascot) and peptides with XCorr scores≥ 1.5 (from Sequest HT) were
allowed. The following criteria were applied to assign proteins as po-
sitively identified: (i) an ANOVA score between experimental groups of
≤0.01, and (ii) proteins with ≥2 peptides matched.
The freely available software packages PANTHER (http://
pantherdb.org/), STRING (https://string-db.org/) and the web-based
gene set analysis toolkit named WebGestalt (http://www.webgestalt.
org/webgestalt_2013/) were used to identify protein class, characterize
potential protein interactions and classify the cellular location of
identified proteins respectively.
2.8. Comparative immunoblot analysis
For the independent evaluation of potential protein changes iden-
tified by mass spectrometry, a comparative immunoblot survey with a
panel of specific antibodies to select muscle proteins was carried out
using total crude extracts from 5-month-old wild-type and age-matched
mdx-4cv hind limb muscle tissue. One-dimensional gel electrophoresis,
silver staining of protein gels and immunoblot analysis was performed
as previously described in detail [47]. Briefly, samples for immunoblot
analysis were prepared in 2× Laemmli buffer heated at 97 °C for 7min
and loaded onto hand-cast 10% sodium dodecyl sulfate polyacrylamide
gels. For comparative analyses, silver staining of protein gels was car-
ried out with 10 μg protein per lane. Immunoblotting was carried out
with 25 μg of protein per lane, with the exception of myelin protein,
which was analysed with 50 μg of protein per gel lane. Proteins were
transferred to nitrocellulose membranes, blocked and incubated in
primary antibody overnight, followed by detection with horseradish
peroxidase conjugated secondary antibodies using the enhanced che-
miluminescence method. Densitometric scanning and statistical ana-
lysis of immunoblots was performed using a HP PSC-2355 scanner and
ImageJ software (NIH, Bethesda, MD, USA) along with Graph-Pad
Prism software (San Diego, CA, USA), in which statistical significance
was based on a p value≤ 0.05.
2.9. Immunofluorescence microscopy
The immunofluorescence microscopical localization of dystrophin
and myoferlin was carried out with wild type versus mdx-4cv skeletal
muscles. Freshly dissected tissue specimens were quick-frozen in liquid
nitrogen-cooled isopentane and 10 μm sections cut in a cryostat [20].
For dystrophin immuno-staining, unfixed cryosections were boiled in
phosphate-buffered saline for 5min as previously described in detail
[48]. Tissue sections were permeabilised in 0.1% (v/v) Triton X-100 for
10min and then blocked with 1:20 diluted normal goat serum for
30min at room temperature. For myoferlin immuno-staining, muscle
tissue sections were fixed in acetone for 10min at room temperature
and then also blocked with normal goat serum as described above.
Primary antibodies to dystrophin and myoferlin were diluted 1:20 and
1:50, respectively, in phosphate-buffered saline for overnight incuba-
tion at 4 °C [20]. Specimens were carefully washed and then incubated
with fluorescently-labelled secondary antibodies, using 1:200 diluted
anti-mouse RRX antibody for 45min at room temperature. Nuclei were
counter-stained with 1 μg/ml bis-benzimide Hoechst 33342. Following
antibody labelling, tissue sections were embedded in Fluoromount G
medium and viewed under a Zeiss Axioskop 2 epifluorescence micro-
scope equipped with a digital Zeiss AxioCam HRc camera (Carl Zeiss
Jena GmbH, Jena, Germany).
3. Results
3.1. Proteomic analysis of the sarcolemma-enriched fraction from skeletal
muscle
The isolation of sufficient quantities of the sarcolemma-enriched
fraction from mouse skeletal muscle for extensive biochemical analyses
is difficult and results in relatively small amounts of membrane vesicles.
Using differential centrifugation in combination with lectin agglutina-
tion, the affinity purification method employed in this study yielded
approximately 70 μg protein per 4 g of starting material. However,
these low amounts of membranes were sufficient to carry out a com-
parative proteomic study on wild type versus mdx-4cv skeletal muscle
tissue. The sarcolemma-enriched fraction contains the plasma mem-
brane region and its actin membrane cytoskeleton and associated in-
tracellular cytoskeleton, and the basal lamina and extracellular matrix,
as well as the neuromuscular junction and attached motor neuron and
Schwann cells [27,28,41]. In addition, abundant membranes and pro-
tein populations from mitochondria, the sarcoplasmic reticulum,
transverse tubules, ribosomes, the Golgi apparatus, the nucleus, the
cytosol, lysosomes, serum and the contractile apparatus are usually
present in agglutinated vesicle preparations from skeletal muscle tissue
[27]. The previous biochemical evaluation of the Dp427 isoform of
dystrophin in mdx sarcolemma preparations using gradient gel elec-
trophoresis and immunoblotting [49] suggests a similar degree of cross-
contaminations in mouse membranes as compared to rabbit prepara-
tions [27]. The gel electrophoretic protein band pattern of the wild type
versus the dystrophin-deficient mouse sarcolemma fraction was shown
to be relatively comparable. However, besides sarcolemma vesicles, a
major class of membranes is derived from the sarcoplasmic reticulum,
as illustrated by the presence of a major band of apparent 110 kDa
consisting of SR Ca2+-ATPases and a high-molecular-mass band above
dystrophin of apparent 560 kDa that represents the RyR1 isoform of the
ryanodine receptor calcium-release channel [49]. Fig. 1 illustrates the
distribution of cellular components in the isolated membrane fraction
from wild type and mdx-4cv preparations, including membranes, mi-
tochondria, macromolecular complexes, envelope, nucleus, en-
doplasmic reticulum, membrane-enclosed lumen, cytoskeleton, cell
projection and the endomembrane system.
The multi-consensus files of identified protein species with high
confidence qualitative results confirmed the presence of crucial mem-
bers of the sarcolemmal dystrophin-glycoprotein complex and key
sarcolemmal marker proteins. The core dystrophin complex was re-
presented by dystrophin isoform Dp427 (P11531), α/β-dystroglycan
(Q62165), α-sarcoglycan (P82350), β-sarcoglycan (P82349), γ-sarco-
glycan (P82348), δ-sarcoglycan (P82347), α1-syntrophin (Q61234) and
sarcospan (Q62147). Sarcolemmal marker proteins included dysferlin
(Q9ESD7), the plasma membrane Ca2+-transporting ATPase isoform
Atp2b1 (G5E829), various subunits of the Na+/K+-ATPase (Q8VDN2,
Q6PIE5, P14094, P97370, P14231), integrins (P05555, P09055,
O70309, Q3V3R4, P43406), annexins A1 and A2 (P10107, P07356),
Na+-channel subunits (Q9ER60, P97952, Q7M729) and the sarco-
lemmal Cl−-channel protein (Q64347). Motor neuron and myelinating
Schwann cell-derived markers were identified as the neural cell adhe-
sion molecule NCAM-1 (P13595-4), the synaptosomal-associated pro-
tein SNAP-23 (O09044), neuroplastin (P97300-3), dystrophin-related
protein DRP-2 (Q05AA6), periaxin (O55103), myelin basic protein
(P04370-4), myelin protein PO (P27573) and myelin protein P2
(P24526).
Components of the sarcolemma-attached basal lamina and extra-
cellular matrix were identified as laminin (Q60675, P02468, P02469),
nidogen (P10493), basement membrane-specific heparan sulfate
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proteoglycan core protein HSPG-2 (Q05793), collagen VI (Q02788,
Q04857), decorin (P28654), lumican (P51885), prolargin (Q9JK53)
and asporin (Q99MQ4). Cytoskeletal proteins associated with the
muscle plasma membrane included synemin (Q70IV5-2), vimentin
(P20152), desmin (P31001), tubulin (P99024, P68369) and vinculin
(Q64727).
3.2. Decreased proteins in dystrophin-deficient sarcolemma from mdx-4cv
muscle
The comparative proteomic analysis of the sarcolemma-enriched
fraction revealed that the full-length Dp427 isoform of dystrophin
(accession number P11531; gene name Dmd), which was recognized by
8 unique peptides (Table 1), is the most reduced protein species in mdx-
4cv hind limb muscle. This agrees with the mutant status of the mdx-4cv
mouse model of Duchenne muscular dystrophy. In analogy, the main
dystrophin-associated glycoproteins α/β-dystroglycan, α-sarcoglycan
and δ-sarcoglycan were shown be greatly reduced in the sarcolemma
fraction from dystrophic skeletal muscles (Table 1). In addition, the
dystrophin-associated glycoprotein β-sarcoglycan (accession number
P82349; gene name Sgcb) was recognized by 1 unique peptide (con-
fidence 41.49; Anova (p) 7.17E-05) and showed a 7.6-fold decrease.
Besides the dystrophin complex, the expression levels of a variety of
metabolic enzymes, components of the motor neuron system,
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Fig. 1. Overview of the subcellular localization of proteins identified in the sarcolemma-enriched fraction from wild type (a, wt) and dystrophic (b, mdx-4cv) mice by mass spectrometry-
based proteomics using multi-consensus data. Shown are the top 10 cellular components based on WebGestalt analysis, filtered on high confidence peptides and on Xcorr scores (default
on Proteome Discover), and only for proteins ≥2 unique peptides.
Table 1
Mass spectrometric identification of proteins with a reduced abundance in the sarcolemma-enriched fraction from dystrophic mdx-4cv skeletal muscle.
Accession Gene name Protein name Unique
peptides
Peptide
count
Confidence score Anova (p) Max fold
change
P11531 Dmd Dystrophin 8 8 255.9 1.26E-05 2708.2
P27573 Mpz Myelin protein P0 2 2 4.6 2.84E-05 33.8
O55103 Prx Periaxin 15 15 566.6 1.95E-11 21.8
Q8BKZ9 Pdhx Pyruvate dehydrogenase protein X component, mitochondrial 2 2 98.2 1.76E-05 16.8
Q62165 Dag1 Dystroglycan 2 2 51.6 1.03E-07 14.8
P41216 Acsl1 Long-chain-fatty-acid–CoA ligase 1 3 3 174.0 9.99E-04 12.2
Q99LC3 Ndufa10 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10,
mitochondrial
2 2 62.5 1.97E-04 8.2
Q8VCT4 Ces1d Carboxylesterase 1D 2 2 82.2 1.64E-04 6.8
Q70IV5 Synm Synemin 2 2 47.7 4.99E-06 5.3
P16330 Cnp 2′,3′-cyclic-nucleotide 3′-phosphodiesterase 3 3 85.5 2.10E-04 4.9
P12367 Prkar2a cAMP-dependent protein kinase type II-alpha regulatory subunit 2 2 3.2 6.95E-05 4.9
A2A863 Itgb4 Integrin beta-4 5 5 160.7 8.49E-05 4.3
P82347 Sgcd Delta-sarcoglycan 3 3 57.6 3.78E-04 4.0
P82350 Sgca Alpha-sarcoglycan 2 2 118.5 3.63E-06 3.7
Q8R1G2 Cmbl Carboxymethylenebutenolidase homolog 2 2 43.1 3.15E-03 3.5
P09411 Pgk1 Phosphoglycerate kinase 1 2 2 3.2 2.01E-06 3.3
P05064 Aldoa Fructose-bisphosphate aldolase A 2 2 49.3 3.86E-05 3.3
Q64521 Gpd2 Glycerol-3-phosphate dehydrogenase, mitochondrial 2 2 83.6 2.75E-04 3.2
Q8BH59 Slc25a12 Calcium-binding mitochondrial carrier protein Aralar1 3 3 129.9 1.55E-03 3.2
Q8R3Z5 Cacnb1 Voltage-dependent L-type calcium channel subunit beta-1 2 2 95.2 1.25E-05 3.1
O09165 Casq1 Calsequestrin-1 2 2 50.3 3.30E-04 3.0
P07310 Ckm Creatine kinase M-type 2 2 72.7 6.54E-03 2.9
Q03265 Atp5a1 ATP synthase subunit alpha, mitochondrial 3 3 107.2 2.52E-05 2.6
P61982 Ywhag 14–3-3 protein gamma 2 2 57.3 5.13E-06 2.4
Q61554 Fbn1 Fibrillin-1 4 4 183.3 2.41E-03 2.2
Q7TQ48 Srl Sarcalumenin 3 3 5.6 4.52E-03 1.7
P14824 Anxa6 Annexin A6 3 3 216.8 1.17E-03 1.6
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cytoskeletal proteins, sarcolemmal receptors and ion-handling proteins
were shown to be reduced. Proteins with decreased abundance in the
sarcolemma-enriched fraction, which were only identified by a single
unique peptide, are listed in the accompanying Data-in-Brief publica-
tion [50].
3.3. Increased proteins in dystrophin-deficient sarcolemma from mdx-4cv
muscle
A large number of proteins with an increased abundance in the
sarcolemma-enriched fraction from mdx-4cv muscle tissue were iden-
tified by mass spectrometric analysis. As listed in Table 2, and Table 1
in the accompanying Data-in-Brief publication [50], protein species
with a significant change ranged from eosinophil-derived granule per-
oxidase to NADPH-dependent retinol dehydrogenase. The proteomic
survey revealed drastic increases in proteins that function in the re-
sponse of the innate immune system, inflammation, various aspects of
cytosolic and mitochondrial metabolism, fibre regeneration, the con-
tractile apparatus, ribosomal protein synthesis, Ca2+-regulation,
maintenance of membrane potential, cell adhesion processes, the cel-
lular stress response, the cytoskeletal network and the extracellular
matrix. Changes in isoforms of contractile proteins and Ca2+-handling
proteins indicate alterations in the fine regulation of the actomyosin
apparatus and the kinetics of ion fluxes involved in excitation-con-
traction coupling in muscular dystrophy. In relation to the dystrophic
phenotype and sarcolemmal adaptations, an interesting finding was the
7.8-fold increase in the plasma membrane repair protein myoferlin
(Table 2). Importantly, this member of the ferlin protein family is
highly homologous to the plasmalemmal protein dysferlin, which was
also identified in this study, but only by 1 peptide (accession number
Q9ESD7; gene name Dysf; confidence 47.53; Anova (p) 0.002839315).
Dysferlin was shown to exhibit a 2.8-fold increase in abundance in the
fraction with mdx-4cv muscle sarcolemma. In addition, proteins with
increased abundance in the sarcolemma-enriched fraction, which were
only identified by a single unique peptide, are listed in the accom-
panying Data-in-Brief publication [50].
The distribution of proteomic changes is summarized in the bioin-
formatic PANTHER diagramme of Fig. 2, which illustrates the wide
Table 2
Mass spectrometric identification of proteins with an increased abundance in the sarcolemma-enriched fraction from dystrophic mdx-4cv skeletal muscle. Additional proteins with an
increased abundance change below 5-fold are listed in Table 1 in the accompanying Data-in-Brief publication [50].
Accession Gene name Protein name Unique peptides Peptide count Confidence score Anova (p) Max fold change
P49290 Epx Eosinophil peroxidase 2 2 3.6 1.60E-13 Infinity
P04441 Cd74 H-2 class II histocompatibility antigen gamma chain 2 2 3.2 1.32E-04 117.4
Q9D1I2 Card19 Caspase recruitment domain-containing protein 19 2 2 57.0 7.26E-04 60.7
Q5SX39 Myh4 Myosin-4 5 5 115.6 5.01E-03 32.9
Q9D0E1 Hnrnpm Heterogeneous nuclear ribonucleoprotein M 2 2 45.8 5.08E-03 32.3
Q5SX40 Myh1 Myosin-1 15 15 800.4 8.51E-04 27.1
P13541 Myh3 Myosin-3 2 2 3.7 4.28E-03 22.7
P01901 H2-K1 H-2 class I histocompatibility antigen, K-B alpha chain 4 4 202.7 1.68E-07 20.1
P06800 Ptprc Receptor-type tyrosine-protein phosphatase C 3 3 214.0 2.87E-07 20.0
P97457 Mylpf Myosin regulatory light chain 2, skeletal muscle isoform 2 2 143.6 9.78E-04 17.2
P62918 Rpl8 60S ribosomal protein L8 3 3 105.0 1.05E-06 13.3
P47964 Rpl36 60S ribosomal protein L36 2 2 3.3 9.55E-03 13.0
Q8BMD8 Slc25a24 Calcium-binding mitochondrial carrier protein SCaMC-1 4 4 214.4 2.91E-05 12.7
Q62230 Siglec1 Sialoadhesin 6 6 302.8 6.83E-05 10.8
P62301 Rps13 40S ribosomal protein S13 2 2 62.7 2.35E-05 10.6
P51881 Slc25a5 ADP/ATP translocase 2 2 2 97.3 1.98E-05 10.3
Q8BMK4 Ckap4 Cytoskeleton-associated protein 4 7 7 229.0 2.47E-05 10.3
Q9D8E6 Rpl4 60S ribosomal protein L4 4 4 97.0 1.01E-05 9.9
P47911 Rpl6 60S ribosomal protein L6 3 3 162.4 4.38E-07 9.4
P43276 Hist1h1b Histone H1.5 4 4 62.0 1.14E-05 8.9
P62245 Rps15a 40S ribosomal protein S15a 3 3 158.8 4.86E-06 8.5
P11835 Itgb2 Integrin beta-2 3 3 102.8 1.04E-04 8.0
Q69ZN7 Myof Myoferlin 5 5 121.4 1.62E-04 7.8
P01872 Ighm Ig mu chain C region 3 3 149.1 4.53E-05 7.4
Q7TPR4 Actn1 Alpha-actinin-1 2 2 42.5 2.98E-05 6.7
Q6ZWV7 Rpl35 60S ribosomal protein L35 2 2 47.0 2.17E-05 6.7
P14148 Rpl7 60S ribosomal protein L7 3 3 109.4 5.97E-08 6.6
Q9D8H7 Oma1 Metalloendopeptidase OMA1, mitochondrial 2 2 4.0 8.43E-07 6.6
P49300 Clec10a C-type lectin domain family 10 member A 3 3 102.0 6.37E-05 6.5
P47963 Rpl13 60S ribosomal protein L13 2 2 47.6 3.83E-08 6.4
Q9WV54 Asah1 Acid ceramidase 3 3 105.4 1.62E-07 6.4
P28653 Bgn Biglycan 2 2 116.0 3.31E-04 6.4
P62754 Rps6 40S ribosomal protein S6 2 2 43.9 5.97E-07 6.4
P43274 Hist1h1e Histone H1.4 6 6 68.9 1.83E-06 6.3
P35979 Rpl12 60S ribosomal protein L12 2 2 64.4 3.07E-04 6.1
Q9CR57 Rpl14 60S ribosomal protein L14 3 3 190.3 1.22E-05 6.1
Q3UMR5 Mcu Calcium uniporter protein, mitochondrial 3 3 130.5 1.43E-05 5.7
Q62465 Vat1 Synaptic vesicle membrane protein VAT-1 homolog 3 3 195.2 2.85E-05 5.7
P53026 Rpl10a 60S ribosomal protein L10a 2 2 55.8 2.67E-05 5.5
P97449 Anpep Aminopeptidase N 4 4 119.0 3.53E-05 5.5
O88990 Actn3 Alpha-actinin-3 8 8 449.6 2.18E-04 5.5
P50285 Fmo1 Dimethylaniline monooxygenase [N-oxide-forming] 1 2 2 67.5 3.49E-04 5.4
P54116 Stom Erythrocyte band 7 integral membrane protein 5 5 308.7 8.74E-05 5.3
Q923B6 Steap4 Metalloreductase STEAP4 3 3 79.0 1.16E-04 5.3
P29788 Vtn Vitronectin 2 2 93.6 6.84E-09 5.3
Q64449 Mrc2 C-type mannose receptor 2 3 3 112.7 2.78E-06 5.3
P10107 Anxa1 Annexin A1 3 3 191.0 1.28E-05 5.2
Q8VHX6 Flnc Filamin-C 4 4 62.2 3.76E-05 5.1
P62702 Rps4x 40S ribosomal protein S4, X isoform 4 4 68.2 9.56E-06 5.0
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range of altered biological functions in muscular dystrophy. The listings
of changed proteins includes 27 decreased proteins (Fig. 2a) and 163
increased proteins (Fig. 2b). Potential protein-protein interaction pat-
terns within the altered protein population in the sarcolemma-enriched
fraction from mdx-4cv skeletal muscles were determined with the
STRING analysis programme. Fig. 3 shows the network analysis of de-
creased versus increased protein species. Interesting patterns emerged
from the decreased core dystrophin complex, consisting of dystrophin
isoform Dp427, dystroglycan and sarcoglycans, and its interactions via
dystroglycan with the Schwann cell scaffolding protein periaxin and
myelin protein PO, as well as the Ca2+-regulatory system (Fig. 3a). Two
major clusters were identified in the increased protein constellation, i.e.
the 40S ribosomal proteins SA, S2, S3, S4, S6, S8, S9, S11, S13, S15,
S16, S18, S23, S25 and the 60S ribosomal proteins L4, L6, L7, L8, L12,
L13, L14, L18, L35, L36 forming supramolecular networks, and the
cytoskeleton-contractile apparatus-extracellular matrix axis (Fig. 3b).
The bioinformatic analysis of the proteomic data sets generated in this
survey of the dystrophin-deficient sarcolemma suggests complex pa-
thophysiological changes in a variety of cellular systems and potential
compensatory mechanisms involving protein synthesis, changes in
contractile protein isoforms and the up-regulation of cytoskeletal pro-
teins.
3.4. Verification of proteomic changes by immunoblot analysis
Key findings from the proteomic analysis of the sarcolemma-en-
riched fraction from mdx-4cv skeletal muscles were verified by im-
munoblotting. However, a serious issue with many commercially
available antibodies is a lack of species, tissue and/or protein isoform
specificity to achieve a satisfactory signal-to-noise ratio. A large number
of tested antibodies to newly identified proteins resulted in extensive
background staining, which prevented their proper assessment by im-
munoblot analysis (not shown). Fig. 4 shows the successful im-
munoblotting of 8 different proteins, including newly identified
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Fig. 2. Overview of changed protein classes in the sarcolemma-enriched fraction from mdx-4cv skeletal muscle. In order to identify the clustering of decreased (a) and increased (b)
protein classes based on the mass spectrometric analysis of sarcolemma preparations from wild type versus mdx-4cv skeletal muscles (Tables 1, 2 and S1), the bioinformatics software
programme PANTHER was used.
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Fig. 3. Overview of potential protein-protein interaction pattern in the sarcolemma-enriched fraction from mdx-4cv skeletal muscle. In order to identify potential protein-protein
interaction pattern of decreased (a) and increased (b) proteins in the sarcolemma fraction from mdx-4cv muscle (Tables 1, 2 and S1), the bioinformatics software programme STRING was
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proteins with a changed abundance in mdx-4cv muscles and previously
established markers of muscular dystrophy-related alteration in protein
expression levels. Silver-staining of a representative gel indicated no
major differences in protein banding patterns between crude wild type
versus mdx-4cv preparations (Fig. 4a). As a control of a major protein
species that exhibits no significant changes in its abundance, the im-
munoblotting of laminin is shown for protein loading of 25 μg and 50 μg
per lane (Fig. 4b, e). The established dystrophin-associated glycoprotein
β-dystroglycan and the recently described cytolinker protein desmo-
glein isoform DSG-1 were both confirmed to be reduced in muscular
dystrophy (Fig. 4c,d), establishing the mutant status of the mdx-4cv
muscle preparations used in this study. Importantly, the mass spectro-
metrically identified myelin PO protein was verified to be of lower
concentration in dystrophinopathy (Fig. 4f). In analogy, increases in the
extracellular matrix component fibronectin, the dystrophin-associated
protein biglycan, the annexin isoform ANX2 and the newly identified
protein dysferlin were confirmed by immunoblotting (Fig. 4g–j).
Fig. 4k–s summarizes the statistical evaluation of the immunoblot
analysis shown in Fig. 4a–j.
3.5. Immunofluorescence microscopy of dystrophic mdx-4cv skeletal muscle
tissue
The histopathological and mutant status of mdx-4cv mouse muscles
were verified by hematoxylin/eosin staining and the immuno-
fluorescence microscopical analysis of the full-length Dp427-M isoform
of dystrophin, respectively. Fig. 5a–d clearly shows that the mdx-4cv
gastrocnemius muscle is almost completely lacking dystrophin at its
surface membrane and that the dystrophic phenotype is associated with
the presence of central nucleation, considerable variations in fibre
diameter and apparent fibrosis and inflammation. The analysis of
myoferlin expression using transverse cryosections of soleus and dia-
phragm muscles confirmed the results from the proteomic survey of the
dystrophin-deficient sarcolemma. Myoferlin was shown to exist at a
higher concentration in slow soleus and severely dystrophic diaphragm
muscle from the mdx-4cv mouse, as compared to wild type (Fig. 5e–l).
The immunofluorescence labelling of myoferlin in gastrocnemius and
tibialis anterior muscle specimens showed relatively poor specific
staining patterns (not shown) and was not further pursued. In wild type
soleus and diaphragm muscles, myoferlin is probably mostly present in
degenerating fibres, and drastically up-regulated in the dystrophic
phenotype.
4. Discussion
The almost complete loss of dystrophin isoform Dp427-M causes a
plethora of secondary changes in dystrophic skeletal muscles that ne-
gatively affect many cellular processes, physiological mechanisms and
biochemical pathways [51]. Under healthy conditions, contractile force
is transmitted between sarcomeric Z-disks and M-lines of myofibrils and
bridged across the sarcolemma towards the extracellular matrix and the
tendon structure. The lack of the dystrophin lattice as a molecular an-
chor and scaffold weakens this crucial structural linkage between the
intracellular cytoskeleton and the extracellular collagen assembly,
which results in impaired lateral force transmission in dystrophic
muscle fibres [52]. The proteomic profiling of the sarcolemma-enriched
fraction from hind limb muscles of the mdx-4cv mouse model of dys-
trophinopathy presented here confirms this highly complex pathophy-
siology [53,54]. Distinct changes in the dystrophin-deficient plasma
membrane agree with the idea of multifaceted secondary alterations
due to the primary abnormality in the sub-sarcolemmal cytoskeleton, as
summarized in Fig. 6. As compared to previous proteomic surveys of
dystrophic muscle tissues [21–23], this systematic analysis with a focus
on the sarcolemmal membrane system and its associated intra- and
extracellular structures has identified interesting new protein altera-
tions, as well as confirmed critical pathobiochemical mechanisms of
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Fig. 4. Immunoblot analysis of altered sarcolemma-associated proteins in dystrophin-deficient mdx-4cv skeletal muscle extracts. Shown is a silver-stained gel (a) and corresponding
immunoblots labelled with antibodies to the basal lamina component laminin (LAM; b,e), β-dystroglycan (β-DG; c), the cytolinker desmoglein isoform 1 (DSG1; d), myelin PO protein
(MPO; f), fibronectin (FN; g), biglycan (BYG; h), annexin A2 (ANX2; i) and dysferlin (DYS; j). Lanes 1 and 2 represent 5-month old wild type (wt) versus age-matched mdx-4cv hind limb
muscle extracts, respectively. In panels (e) and (f), 50 μg protein/lane, and in all other panels 25 μg protein/lane were loaded. Molecular mass standards are marked on the left of panels.
The comparative immunoblotting of laminin (k, n), β-dystroglycan (l), the cytolinker desmoglein isoform 1 (m), myelin PO protein (o), fibronectin (p), biglycan (q), annexin A2 (r) and
dysferlin (s) between crude extracts from wild type versus mdx-4cv mice was statistically evaluated using an unpaired Student's t-test (Mean values ± SEM; n=4; *p < 0.05;
**p < 0.01; ***p < 0.001).
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muscular dystrophy.
Proteome-wide changes associated with muscular dystrophy include
significant alterations in noteworthy protein species involved in plas-
malemmal repair, cellular signalling, ion handling, innervation, fibre
regeneration, protein synthesis, the excitation-contraction-relaxation
cycle, energy metabolism, metabolite transportation, the innate im-
mune response, the cytoskeletal network and the extracellular matrix.
Large-scale profiling approaches using comparative organellar pro-
teomics are usually complicated by both technical and biological issues
[55–57]. In the case of the muscle surface membrane isolated from
mutant mouse hind limb homogenates, the following bioanalytical
obstacles should therefore be taken into account during the inter-
pretation and extrapolation of mass spectrometric findings: (i) the
sarcolemmal subproteome embodies only a small percentage of the
constituents of the entire skeletal muscle proteome, therefore requiring
the pooling of individual subtypes of slow, mixed and fast muscles for
the initial proteomic screening procedure, (ii) skeletal muscle tissues
are heterogeneous in composition and contain besides various types of
extrafusal contractile fibres also motor neurons, immune cells, capil-
laries, satellite cells, muscle spindles and several complex layers of
connective tissue and tendons, and (iii) subcellular fractionation pro-
tocols for the enrichment of the plasmalemma membrane that employ
differential centrifugation and affinity agglutination approaches, are
often complicated by a considerable amount of cross-contamination due
to protein desorption, adsorption and vesicular entrapment [56]. If
these analytical issues are properly considered, the subproteomic ana-
lysis of the enriched plasmalemma can be highly useful, since it en-
compasses the crucial advantage of firmly reducing sample complexity.
This should decisively improve the coverage of protein species be-
longing to the sarcolemma-cytoskeleton-extracellular matrix axis of the
skeletal muscle periphery.
The proteomic profiling of the mdx-4cv sarcolemma clearly con-
firmed dystrophin as the most drastically decreased protein in muscular
dystrophy and the concomitant reduction in the expression of the core
members of the dystrophin-associated glycoprotein complex, i.e. dys-
troglycans and sarcoglycans [8]. Immunoblotting also confirmed the
lower concentration of β-dystroglycan and the dystrophin-associated
cytolinker desmoglein [38]. In contrast, isoforms of the plasma mem-
brane scaffolding protein flotillin, which is closely associated with ca-
veolin-3 within caveolar membranes that are void of the dystrophin-
complex [58], was shown to be increased in the Dp427-deficient sar-
colemma. An interesting new aspect of the muscular dystrophy-in-
itiating disintegration of the dystrophin complex is the identification of
a reduced expression of the heteropolymeric intermediate filament
protein synemin, which was previously shown to be linked to dystro-
phin and utrophin [37]. In contrast to synemin, the indirectly dystro-
phin-linked proteins vimentin and tubulin are increased in mdx-4cv
muscle and this probably represents compensatory processes to rescue
the dystrophin-lacking cytoskeleton [18,43]. In skeletal muscle fibres,
cytoplasmic synemin is associated with desmin and vimentin filaments
and thereby contributes to cellular resilience by supporting cell shape,
adhesion and migration [59]. Synemin and its association with the in-
termediate filament network strengthens the linkage between myofi-
brils and sarcolemmal costamers, as well as the plasmalemma region at
the neuromuscular and myotendinous junctions. Since intermediate
filaments surround the Z-lines, this cytoskeletal structure links sarco-
meric units of myofibrils to costameres and provides mechanical sta-
bility to contractile cells [2]. Hence, reduced levels of synemin may
play a central role in the secondary pathobiochemical changes that
render dystrophin-deficient fibres more susceptible to micro-rupturing
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Fig. 5. Histological and immunofluorescence microscopical analysis of dystrophic mdx-4cv skeletal muscle. Shown are transverse sections of gastrocnemius (a–d), soleus (e, f) and
diaphragm (g, h) muscles from 6-month old wild type (a, c, e, g; wt) and dystrophic (b, d, f, h; mdx-4cv) mice. Cryosections were stained with hematoxylin and eosin (H&E; a, b), as well as
immuno-labelled with antibodies to the full-length dystrophin isoform Dp427 (c, d) and myoferlin (e–h). Bar equals 50 μm.
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of the disintegrating sarcolemma.
The potentially impaired linkage of synemin to the sub-sarcolemmal
cytoskeleton of the neuromuscular junction [59] is an interesting result
in connection with the identified reduction of myelin protein PO and
periaxin. Myelin protein PO is crucial for the maintenance and func-
tionality of peripheral myelin, and the scaffolding protein periaxin is an
integral member of the dystroglycan complex in Schwann cells, which
also contains the dystrophin-related protein isoform DRP2 [60]. Lower
levels of these glia cell components indicate muscular dystrophy-related
changes in the motor neuron system especially related to peripheral
nerve myelination, and agree with the previously described remodel-
ling of both pre- and postsynaptic regions of the neuromuscular junc-
tion during dystrophic progression [61]. In contrast to Schwann cell
markers, the neural cell adhesion molecule NCAM1 and the synaptic
vesicle membrane protein VAT1 were shown to be increased in the
sarcolemma-enriched fraction from dystrophic muscle. The VAT1 pro-
tein is involved in vesicular transport and important for the overall
process of neurotransmitter storage and release at cholinergic synapses.
In mature skeletal muscle, NCAM1 is mostly located at the motor
endplate and not the sarcolemma [62], but its expression increases
during muscle fibre regeneration [63]. Thus, the occurrence of elevated
NCAM1 levels would match the concept of adaptive process in the
dystrophic phenotype and degeneration-regeneration cycles in the
neuromuscular system [64].
Fibre regeneration, muscle adaptations, an enhanced cellular stress
response and membrane reestablishment, as well as the activation of
the innate immune system, are in agreement with the proteomic iden-
tification of drastically increased proteins belonging to the ferlin and
annexin family of repair proteins, immune cell markers, molecular
chaperones and ribosomal components. The considerable levels of 40S
and 60S ribosomal proteins involved in protein synthesis is indicative of
major regenerative processes occurring during repair cycles in dys-
trophic muscle tissue. The enrichment in ribosomal components is most
likely not due to direct interactions of ribosomes with the sarcolemma,
but more likely due to the fact that the sarcolemma-enriched fraction
contains a high degree of cross-contamination from other organelles
and membrane systems. However, although an immunohistological
study indicates that ribosomes are majorly located in the inter-myofi-
brillar cytoplasm, they appear to also reside in the sub-sarcolemmal
space in skeletal muscle fibres [65]. Myoferlin, dysferlin and annexins,
in conjunction with the stabilising effect of the cortical actin cytoske-
leton, are critical factors in muscle membrane fusion events and the
Ca2+- and membrane injury-related repair of the sarcolemma [66–68].
Dysferlin and myoferlin also regulate transverse tubule formation and
Ca2+-homeostasis, making them crucial players in the establishment of
the fibre periphery, its membrane invaginations and ion regulation
[69,70]. Plasma membrane repair and efficient resealing are essential
protective mechanisms for the swift recovery from fibre injury [71].
The proteomic establishment of elevated levels of myoferlin [18] and its
closely related isoform dysferlin agree with previous cell biological
studies on membrane repair and vesicle wound patching in muscular
dystrophy [72,73]. The identification of increases in annexin A1 [74]
supports the previous demonstration that annexins are universal mar-
kers of dystrophinopathy [43]. Hence, the increased concentration of
myoferlin, dysferlin and the Ca2+-triggered phospholipid-binding iso-
form A1 of annexin in the dystrophin-deficient sarcolemma strongly
indicates plasmalemmal wound-healing to counteract detrimental
membrane rupturing. Annexin A1 is also a critical factor for the re-
storation of cellular homeostasis by modulating the inflammatory re-
sponse [75].
Increased levels of inflammatory modifiers are in line with the
finding that the protein species with the most highly elevated con-
centration in the sarcolemma-enriched fraction from mdx-4cv muscle
are markers of immune cells, including eosinophil peroxidase [76],
subunits of the histocompatibility complex [77] and receptor-type
tyrosine-protein phosphatase C, which is a positive regulator of T-cell
co-activation [78]. In addition, other immune cell markers included
sialoadhesin and macrophage mannose receptor. Interestingly, the 60-
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Fig. 6. Diagrammatic summary of altered subcellular processes in dystrophic mdx-4cv skeletal muscle as revealed from the proteomic profiling of a sarcolemma-enriched fraction.
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fold increased caspase recruitment domain-containing protein Card19
was previously shown to counteract the activating effects of the protein
Blc10 on the nuclear factor NF-kappa-B and its central role in innate
immunity [79]. Cellular immune responses and sterile inflammation
clearly contribute to muscular changes in dystrophinopathy [80–82].
However, it is not fully understood whether the inflammatory process
in degenerating muscles is mostly due to a pathophysiological me-
chanism that promotes fibre wasting independent of sarcolemmal
rupturing, or if it is based on the relatively non-specific and reactive
invasion of macrophages and other immune cells in necrotic muscle
cells [83,84]. Importantly, serum analyses of dystrophinopathy showed
increased levels of the acute phase response plasma marker haptoglobin
[85], which is a robust indicator of tissue damage-induced inflamma-
tion [45]. Thus, the proteomic identification of immune cell markers in
the sarcolemma fraction from dystrophic muscles supports the concept
that immune cell infiltration is a key feature of degenerating muscle
fibres in Duchenne muscular dystrophy [86].
In agreement with previous proteomic studies of the severely fi-
brotic mdx diaphragm muscle [14], young mdx hind limb muscles
during the acute phase of Dp427 deficiency [87] and the moderately
dystrophic mdx quadriceps femoris muscle [38], this report confirmed
that lack of dystrophin triggers an enhanced cellular stress response in
dystrophic fibres. Molecular chaperone activities are essential for the
safeguarding of proteostasis by averting cytotoxic levels of detrimental
protein aggregation. This is achieved by promoting the efficient re-
moval of irreversibly misfolded protein structures, as well as the in-
itiation of refolding to stabilise compromised, but salvageable proteins.
A variety of stress proteins, including the heat shock proteins HSPB5,
HSPB7, HSPA and HSPC are elevated in dystrophic muscles and pro-
mote accelerated peptide folding to support skeletal muscle proteins to
resume their proper functional fold [88]. The increased expression of
the small heat shock protein HSPB1 of 27 kDa, the collagen-specific
molecular chaperone HSP47 (serpin H1) and the enzyme protein-dis-
ulfide isomerase, as determined here by comparative proteomics, il-
lustrates that molecular chaperones play an important role in the pre-
vention of proteotoxic side effects in dystrophinopathy.
In the adult skeletal musculature, the ratio of slow, fast and hybrid
fibres relate to the functional demands of individual muscle subtypes.
Distinct shifts in fibre types correlate usually with concomitant changes
in the density or isoform expression pattern of the main protein species
involved in the contraction-relaxation cycle, bioenergetic pathways,
cellular signalling complexes and the Ca2+-handling apparatus. As re-
viewed by Dowling et al. [89], clear fibre type shifting is observed in
individual skeletal muscles during drastic changes in body weight,
diabetes mellitus, cancer cachexia, disuse atrophy, motor neuron dis-
ease, myotonia, inflammatory myopathies, autoimmune muscle dis-
eases, myofibrillar myopathies and age-related muscle wasting. In the
many forms of muscular dystrophy, moderate fibre type conversions
occur whereby slow-twitching fibre populations have a tendency to
undergo degenerative processes later than fast type IIb fibres in dys-
trophinopathy [90]. Remarkably, one-quarter of all fibres in Duchenne
patients exhibit only the adult slow isoform of myosin heavy chain,
whereby the disruption of MyHC gene switching between the mature
fast and slow MyHC isoforms coincides with the deletion in dystrophin
[91]. Previous proteomic studies indicate moderate alteration in the
isoform expression patterns of myosin, actin, actinin, myozenin, myo-
mesin, tropomyosin and troponin [14–16,18,87,92,93]. In this study
focusing on the sarcolemma-enriched fraction, co-purifying proteins
derived from the sarcomere, sarcoplasmic reticulum, mitochondria and
cytosol of dystrophic fibres revealed some impact on fibre specification.
This included increases in contractile myosin heavy chains MyHC-2×,
MyHC-2b and embryonic myosin-3, as well as cellular myosin-9, α-
actinin-1 and fast myosin-binding protein C [94]. Mitochondrial pro-
teins are differentially expressed in mdx-4cv muscles with complex
changes in many enzymes and metabolite carriers involved in bioe-
nergetics and regulatory processes, including pyruvate dehydrogenase,
NADH dehydrogenase, ATP synthase, metalloendopeptidase, ADP/ATP
translocase, Ca2+-uniporter, ferrochelatase and aldehyde dehy-
drogenase. The glycolytic enzymes phosphoglycerate kinase and aldo-
lase were shown to be reduced in dystrophic muscle [95]. These results
demonstrate complex changes in bioenergetic pathways and the con-
traction-relaxation cycle, but no clear fibre type switching that involves
parallel changes in metabolism and contraction kinetics.
In support of previous findings on altered excitation-contraction
coupling and impaired ion handling in dystrophinopathy, this study
confirmed altered levels of certain isoforms of Ca2+-channels, Ca2+-
ATPases and luminal Ca2+-binding proteins. There appears to be a
switch in the slow CSQ2 and fast CSQ1 isoform of the Ca2+-buffering
protein calsequestrin of the terminal cisternae region [96], a reduction
in the Ca2+-shuttle protein sarcalumenin of the longitudinal tubules
[97], a lower concentration of the β-subunit of the voltage-sensing L-
type Ca2+-channel of the transverse tubules, and apparent increases in
the ryanodine receptor Ca2+-release channel of the triad junction, the
slow SERCA2 Ca2+-pump of the sarcoplasmic reticulum, the sarco-
lemmal PMCA-type Ca2+-ATPase, and the stromal interaction molecule
Stim1 that activates store-operated Ca2+-channels in the plasma
membrane. These changes in major Ca2+-handling proteins reflect the
central pathophysiological role of abnormal ion fluxes in muscular
dystrophy, which is linked to the chronic influx of Ca2+-ions through
the leaky plasma membrane, elevated cytosolic Ca2+-levels triggering
proteolytic degradation cycles and an impaired luminal Ca2+-buffering
capacity in dystrophic muscle fibres [51,53]. In addition, up-regulation
of the sarcolemmal Na+/K+-ATPase in damaged fibres indicates a
compensatory mechanism in muscular dystrophy that attempts to
normalise aberrant cation fluxes and thereby stabilise the membrane
potential over the dystrophin-deficient sarcolemma [18,98].
Besides progressive fibre wasting, sterile inflammation and cellular
stress, another key feature of the dystrophic phenotype is reactive
myofibrosis [99]. In contrast to the dystrophin-deficient and fibrotic
heart muscle [44], the expression of the basal lamina component la-
minin-211 is unchanged in dystrophic skeletal muscle, which was also
shown here by immunoblotting. However, the current study shows that
integrins exhibit differential concentration changes, possibly as a
compensatory mechanism to counteract the loss of the dystrophin-
dystroglycan linkage to the basal lamina. Higher levels of extracellular
matrix proteins were previously described in a variety of proteomic
studies, including dermatopontin, periostin, mimecan, asporin, decorin,
fibronectin, collagen I and collagen VI [16,20,43,100]. The analysis of
the sarcolemma membrane system from the dystrophic mdx-4cv mouse
showed an increased concentration in biglycan, fibronectin, vitronectin
and the collagen COL α-1 and COL α-2 VI-chains, which agrees with
previous biochemical investigations into muscular dystrophy-related
myofibrosis [22]. The observed muscular dystrophy-associated turn-
over within the complex collagen system of the extracellular matrix is
also evident by the identification of an increased concentration of the
collagen-specific molecular chaperone named serpin H1, which is more
commonly classified as heat shock protein HSP47 [101]. HSP47 plays a
key role in collagen biosynthesis. High levels of collagens and other
extracellular matrix proteins cause progressive tissue scarring resulting
in a critical loss of muscle elasticity [22], and therefore probably play a
central role in the secondary abnormalities of X-linked muscular dys-
trophy [99].
5. Conclusion
X-linked muscular dystrophy is a highly complex neuromuscular
disorder with intricate pathophysiological changes and compensatory
adaptations on the molecular and cellular level. Dystrophinopathy is
characterized by progressive fibre degeneration, fatty tissue replace-
ment, reactive myofibrosis and sterile inflammation. Previous pro-
teomic studies have confirmed complex changes in a variety of protein
families involved in muscle contraction, cellular signalling, energy
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metabolism, ion handling and the stress response. Based on these
findings, an organellar proteomic profiling survey was initiated with a
focus on the sarcolemma membrane and its associated intra- and ex-
tracellular structures. Subproteomic results were analysed by bioinfor-
matics and key findings confirmed by immunoblotting and immuno-
fluorescence microscopy. Dystrophin and its tightly associated
glycoproteins were shown to be greatly reduced, as well as the inter-
mediate filament component synemin. In contrast, the extracellular
dystrophin complex-linked proteoglycan biglycan and the cytoskeletal
element vimentin exhibited an increased abundance in dystrophin-de-
ficient muscles, probably representing compensatory mechanisms. The
initiation of membrane repair processes and increased protein synthesis
was indicated by high levels of myoferlin, dysferlin and annexin A1,
and various ribosomal protein subunits, respectively. Interestingly, re-
ductions in the scaffolding protein periaxin and myelin PO protein of
Schwann cells suggest changed myelination levels of motor neurons in
muscular dystrophy. Besides confirming changes in metabolic path-
ways, disturbed ion homeostasis, increased levels of molecular cha-
perones and collagen deposition related to myofibrosis, the analysis of
the sarcolemma established considerable levels of invading immune
cells, which agrees with a highly active innate immune system in
muscular dystrophy.
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